UA100372C2 - Выделенный пептид, способный индуцировать цитотоксические т-клетки, и его применение в качестве вакцины - Google Patents

Выделенный пептид, способный индуцировать цитотоксические т-клетки, и его применение в качестве вакцины

Info

Publication number
UA100372C2
UA100372C2 UAA200909469A UAA200909469A UA100372C2 UA 100372 C2 UA100372 C2 UA 100372C2 UA A200909469 A UAA200909469 A UA A200909469A UA A200909469 A UAA200909469 A UA A200909469A UA 100372 C2 UA100372 C2 UA 100372C2
Authority
UA
Ukraine
Prior art keywords
cells
vaccine
isolated peptide
induce cytotoxic
peptide
Prior art date
Application number
UAA200909469A
Other languages
English (en)
Ukrainian (uk)
Inventor
Такуя Цунода
Рюдзі Охсава
Original Assignee
Онкотерапі Саєнс, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Онкотерапі Саєнс, Інк. filed Critical Онкотерапі Саєнс, Інк.
Publication of UA100372C2 publication Critical patent/UA100372C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464422—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46443—Growth factors
    • A61K39/464434—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464462—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Изобретение относится к выделенному пептиду, способному индуцировать цитотоксические Т-клетки, фармацевтической композиции, которая его содержит, эксзосоме, которая экспрессирует на своей поверхности комплекс, включающий данный пептид, способу индуцирования антигенпрезентирующей клетки. Изобретение также относится к способу индуцирования цитотоксичных Т-клеток, вакцине для ингибирования пролиферации клеток, способу скрининга пептида и т.п.
UAA200909469A 2007-02-21 2008-02-21 Выделенный пептид, способный индуцировать цитотоксические т-клетки, и его применение в качестве вакцины UA100372C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90294907P 2007-02-21 2007-02-21

Publications (1)

Publication Number Publication Date
UA100372C2 true UA100372C2 (ru) 2012-12-25

Family

ID=39709837

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200909469A UA100372C2 (ru) 2007-02-21 2008-02-21 Выделенный пептид, способный индуцировать цитотоксические т-клетки, и его применение в качестве вакцины

Country Status (28)

Country Link
EP (20) EP2476693B1 (ru)
JP (6) JP5239103B2 (ru)
KR (8) KR101511140B1 (ru)
CN (4) CN103351423B (ru)
AR (1) AR068302A1 (ru)
AU (1) AU2008218463B2 (ru)
BR (1) BRPI0808421B1 (ru)
CA (3) CA2992074C (ru)
CO (1) CO6190536A2 (ru)
CY (2) CY1114590T1 (ru)
DK (3) DK2476694T3 (ru)
ES (6) ES2540893T3 (ru)
HK (7) HK1172043A1 (ru)
HR (3) HRP20131044T1 (ru)
IL (10) IL200478A (ru)
MX (4) MX2009009022A (ru)
MY (2) MY155029A (ru)
NZ (4) NZ602122A (ru)
PH (1) PH12014501642B1 (ru)
PL (3) PL2476694T3 (ru)
PT (2) PT2465864E (ru)
RU (1) RU2464275C2 (ru)
SG (3) SG10201506589WA (ru)
SI (3) SI2465864T1 (ru)
TW (5) TWI610939B (ru)
UA (1) UA100372C2 (ru)
WO (1) WO2008102557A1 (ru)
ZA (1) ZA200905881B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660677A2 (en) 2003-08-20 2006-05-31 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
BRPI0816236A2 (pt) 2007-08-20 2015-08-18 Oncotherapy Science Inc Peptídeo cdh3 e agente medicinal contendo o mesmo
US8435749B2 (en) 2008-06-30 2013-05-07 Oncotherapy Science, Inc. Anti-CDH3 antibodies labeled with radioisotope label and uses thereof
TWI543767B (zh) * 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
TW201008574A (en) * 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
ES2541325T3 (es) * 2008-10-22 2015-07-17 Oncotherapy Science, Inc. Péptido de epítopo RAB6KIFL/KIF20A y vacunas que contienen el mismo
TWI539160B (zh) * 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
RU2011130796A (ru) 2008-12-24 2013-01-27 Онкотерапи Сайенс, Инк. Пептиды c1orf59 и содержащие их вакцины
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
EP3450459B1 (en) 2009-12-28 2021-05-26 OncoTherapy Science, Inc. Anti-cdh3 antibodies and uses thereof
DK2547359T3 (en) 2010-03-15 2016-06-06 The Board Of Trustees Of The Univ Of Illionis Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS
TWI538685B (zh) 2010-04-02 2016-06-21 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
MY166516A (en) * 2010-12-02 2018-07-05 Oncotherapy Science Inc Tomm34 peptides and vaccines including the same
KR102355121B1 (ko) 2011-12-14 2022-02-09 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 암 요법을 위한 병립 유전자 비활성화 생물표식과 표적들
CN104168917A (zh) * 2012-03-09 2014-11-26 肿瘤疗法科学股份有限公司 含有肽的医药组合物
US9644010B2 (en) * 2012-07-10 2017-05-09 Oncotherapy Science, Inc. LY6K epitope peptides for TH1 cells and vaccines containing the same
JP6259983B2 (ja) * 2012-07-10 2018-01-17 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＫＩＦ２０Ａエピトープペプチドおよびこれを含有するワクチン
HUE036243T2 (hu) 2012-08-31 2018-06-28 Vasculead Inc PSF1-származék peptid
PL2895600T3 (pl) 2012-09-11 2020-10-05 Oncotherapy Science, Inc. Peptydy UBE2T i szczepionki je zawierające
WO2014141652A1 (en) * 2013-03-11 2014-09-18 Oncotherapy Science, Inc. Smyd3 peptides and vaccines containing the same
TWI658049B (zh) * 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
US20160166666A1 (en) * 2013-07-12 2016-06-16 Sumitomo Dainippon Pharma Co., Ltd. Tumor antigen peptide
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
EP3164417A1 (en) 2014-07-01 2017-05-10 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
ES2856834T3 (es) * 2014-08-04 2021-09-28 Oncotherapy Science Inc Péptido derivado de URLC10 y vacuna que contiene el mismo
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CN104975082B (zh) * 2015-06-05 2018-11-02 复旦大学附属肿瘤医院 一组用于评估肺癌预后的基因及其应用
AU2017240745B2 (en) * 2016-03-31 2021-08-19 Biontech Us Inc. Neoantigens and methods of their use
CN110214144B (zh) * 2016-11-16 2023-05-02 深圳华大生命科学研究院 多肽及其应用
AU2018213890B2 (en) 2017-01-25 2023-07-20 Ose Immunotherapeutics Method for manufacturing a stable emulsion for peptide delivery
EP3601539A4 (en) * 2017-03-28 2021-01-13 Zhenglun Zhu METHODS OF TREATING NEOPLASIC DISEASES
JP7364237B2 (ja) * 2017-08-10 2023-10-18 グッド ティー セルズ、 インコーポレイテッド 癌治療のためのｔ細胞の活性化方法
CN111788214B (zh) * 2018-02-15 2021-06-22 国立大学法人旭川医科大学 癌症抗原肽
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
KR102335916B1 (ko) * 2019-04-22 2021-12-08 한국과학기술연구원 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
CN117143206B (zh) * 2023-08-03 2024-09-03 华南农业大学 Alv-j mhc-b21限制性表位肽及其筛选方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
NZ231899A (en) * 1985-10-03 1991-07-26 Genentech Inc Human or porcine inhibin peptide compositions and dna encoding them
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IL103928A0 (en) * 1991-12-11 1993-04-04 American Home Prod Expression of specific immunogens using viral antigens
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
JPH09512167A (ja) * 1994-04-15 1997-12-09 アムジエン・インコーポレーテツド Ｈｅｋ５、ｈｅｋ７、ｈｅｋ８、ｈｅｋ１１、新規なｅｐｈ様受容体タンパク質チロシンキナーゼ
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
WO1997005900A1 (en) 1995-08-03 1997-02-20 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6294378B1 (en) 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
AU6795898A (en) * 1997-04-04 1998-10-30 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
KR100631766B1 (ko) * 1997-10-07 2006-10-09 오노 야꾸힝 고교 가부시키가이샤 폴리펩티드, 그 폴리펩티드를 암호화하는 ｃＤＮＡ 및그들의 용도
US20070014787A1 (en) * 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
WO2001029221A2 (en) * 1999-10-20 2001-04-26 Zymogenetics, Inc. Proteins and polynucleotides encoding them
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
CN1469926A (zh) * 2000-03-29 2004-01-21 科里克萨有限公司 治疗和诊断肺癌的组合物和方法
AU2001278076A1 (en) * 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-5 proteins and related reagents and methods of use thereof
US6830885B1 (en) * 2000-08-18 2004-12-14 Phenogene Therapeutiques Inc. Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN100400099C (zh) * 2001-01-04 2008-07-09 北京迪威华宇生物技术有限公司 预防和治疗人前列腺癌的重组蛋白疫苗
AU2002311787A1 (en) * 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
WO2002086443A2 (en) * 2001-04-18 2002-10-31 Protein Design Labs, Inc Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
MXPA03011979A (es) * 2001-06-18 2005-04-08 Eos Biotechnology Inc Metodos de diagnostico de cancer de ovario composiciones y metodos para rastrear moduladores de cancer de ovario.
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
JP2005536186A (ja) * 2002-03-07 2005-12-02 ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ リンパ管および血管内皮細胞遺伝子
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
EP1594447A2 (en) * 2002-10-02 2005-11-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003300680A1 (en) * 2002-12-10 2004-07-09 Centre National De La Recherche Scientifique Cnrs Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
US20040235071A1 (en) * 2002-12-20 2004-11-25 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476, 62113, 64316, 12264, 32362, 58198, 2887, 3205, 8557, 9600, 9693, 44867, 53058, 55556, 57658, 2208, 10252, 10302, 14218, 33877, 10317, 10485, 25964, 14815, 1363, 1397, 14827, 21708, 3801, 64698, 2179 or 13249
TWI324608B (en) * 2003-02-28 2010-05-11 Oncotherapy Science Inc Genes and polypeptides relating to human colorectal cancers
WO2005001138A2 (en) * 2003-06-18 2005-01-06 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1660677A2 (en) * 2003-08-20 2006-05-31 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
US20070253954A1 (en) * 2004-02-27 2007-11-01 Oncotherapy Science, Inc. Epha4 As Therapeutic Target Of Prc And Pdaca
KR101234281B1 (ko) * 2004-04-09 2013-02-18 가부시키가이샤 진케어켄큐쇼 염색체 안정화에 관한 유전자를 표적으로 하는 암세포 특이적 아포토시스 유도제
EP1756147A2 (en) * 2004-06-01 2007-02-28 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
CN100381460C (zh) * 2004-11-30 2008-04-16 北京市肿瘤防治研究所 Her-2模拟抗原表位及含有该表位的肽
EP1859266A4 (en) * 2005-02-24 2010-07-28 Cemines Inc COMPOSITIONS AND METHODS FOR CLASSIFYING BIOLOGICAL SAMPLES
PT2325306E (pt) * 2005-02-25 2014-04-29 Oncotherapy Science Inc Vacinas peptídicas para cancros do pulmão que expressam polipéptidos ttk, urlc10 ou koc1
CN100348614C (zh) * 2005-06-03 2007-11-14 北京大学 一种肝癌－睾丸特异性抗原蛋白质和抗原肽
RU2395519C2 (ru) * 2005-08-09 2010-07-27 Онкотерапи Сайенс, Инк. Глипикан-3 (gpc3)-производные антигенные пептиды, отторгающие опухоли, используемые для нla-a2-положительных пациентов, и фармацевтическая продукция, включающая их
WO2007018047A1 (ja) * 2005-08-09 2007-02-15 Kurume University Hla-a24分子結合性扁平上皮癌抗原由来ペプチド
KR101130597B1 (ko) 2005-09-13 2012-04-02 다카라 바이오 가부시키가이샤 Ｔ 세포 리셉터 및 그 리셉터를 코드하는 핵산
US20090263832A1 (en) * 2005-11-30 2009-10-22 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in Leukemia Signaling Pathways
EP2002259B1 (en) * 2006-04-10 2012-05-16 Genentech, Inc. Disheveled PDZ modulators
CA2655361C (en) * 2006-06-16 2014-10-07 Kumamoto University Sparc-derived tumor rejection antigenic peptides and medicaments comprising the same
EP1972639A3 (en) * 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1983003A3 (en) * 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
BRPI0816236A2 (pt) * 2007-08-20 2015-08-18 Oncotherapy Science Inc Peptídeo cdh3 e agente medicinal contendo o mesmo
EP2080812A1 (en) * 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
TWI543767B (zh) * 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
EP2483690A1 (de) * 2009-09-29 2012-08-08 Protagen AG Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung

Also Published As

Publication number Publication date
JP2016094459A (ja) 2016-05-26
JP5239103B2 (ja) 2013-07-17
KR20140130507A (ko) 2014-11-10
EP2570430A3 (en) 2013-07-10
HRP20141233T1 (hr) 2015-02-27
KR101511134B1 (ko) 2015-04-28
SI2121731T1 (sl) 2013-10-30
EP2573109A2 (en) 2013-03-27
PL2476694T3 (pl) 2015-04-30
EP2570429A2 (en) 2013-03-20
TW201422637A (zh) 2014-06-16
KR101644877B1 (ko) 2016-08-03
EP2594582A3 (en) 2013-08-14
EP2121731B1 (en) 2013-08-14
HK1172043A1 (en) 2013-04-12
IL219040A (en) 2014-12-31
SI2465864T1 (sl) 2014-12-31
EP2465864A2 (en) 2012-06-20
ES2532708T3 (es) 2015-03-31
CA2678755C (en) 2016-04-26
ES2527397T3 (es) 2015-01-23
JP2013091645A (ja) 2013-05-16
PH12014501642A1 (en) 2015-12-02
TW201538522A (zh) 2015-10-16
KR20130023407A (ko) 2013-03-07
EP2476695A3 (en) 2012-12-12
EP2465866A2 (en) 2012-06-20
DK2476694T3 (en) 2014-12-08
HK1172346A1 (en) 2013-04-19
MX337456B (es) 2016-03-03
BRPI0808421B1 (pt) 2021-10-05
IL219048A0 (en) 2012-05-31
IL219042A0 (en) 2012-05-31
IL219043A (en) 2014-12-31
EP2465866A3 (en) 2012-10-10
DK2121731T3 (da) 2013-10-21
TWI438207B (zh) 2014-05-21
WO2008102557A1 (en) 2008-08-28
AR068302A1 (es) 2009-11-11
TW201433574A (zh) 2014-09-01
TW200844111A (en) 2008-11-16
CA2992074C (en) 2021-01-05
CY1114590T1 (el) 2016-10-05
EP2465864B1 (en) 2014-10-08
HK1134507A1 (en) 2010-04-30
TWI596109B (zh) 2017-08-21
HK1172041A1 (en) 2013-04-12
EP2594582A2 (en) 2013-05-22
EP2476692B1 (en) 2015-04-15
JP5239104B2 (ja) 2013-07-17
EP2567971A2 (en) 2013-03-13
SI2476694T1 (sl) 2015-02-27
EP2567971A3 (en) 2013-06-26
JP5608953B2 (ja) 2014-10-22
EP2465864A3 (en) 2012-10-03
EP2583976A2 (en) 2013-04-24
EP2573109A3 (en) 2013-06-19
ES2541863T3 (es) 2015-07-27
EP2583976A3 (en) 2013-10-23
EP2476693A3 (en) 2012-10-03
HK1172345A1 (en) 2013-04-19
EP2574623A3 (en) 2013-07-17
MX359680B (es) 2018-09-28
PT2121731E (pt) 2013-10-24
EP2573110A3 (en) 2013-09-04
EP2465867A2 (en) 2012-06-20
JP5874158B2 (ja) 2016-03-02
KR20150116463A (ko) 2015-10-15
SG10201909675QA (en) 2019-11-28
TWI494319B (zh) 2015-08-01
EP2574623A2 (en) 2013-04-03
EP2476693A2 (en) 2012-07-18
CN101663315A (zh) 2010-03-03
CA2992074A1 (en) 2008-08-28
EP2476692A3 (en) 2012-12-19
NZ579768A (en) 2012-03-30
DK2465864T3 (en) 2014-11-24
IL219043A0 (en) 2012-05-31
IL219044A0 (en) 2012-05-31
EP2465865A2 (en) 2012-06-20
KR20160045939A (ko) 2016-04-27
AU2008218463B2 (en) 2013-01-17
IL219045A0 (en) 2012-05-31
EP2476694A2 (en) 2012-07-18
EP2573110A2 (en) 2013-03-27
CN101663315B (zh) 2014-10-15
HK1172344A1 (en) 2013-04-19
ES2540893T3 (es) 2015-07-14
EP2476692A2 (en) 2012-07-18
EP2476693B1 (en) 2014-12-24
RU2009135020A (ru) 2011-03-27
EP2121731A4 (en) 2010-04-21
JP5614761B2 (ja) 2014-10-29
CN104292299B (zh) 2017-09-29
IL219041A (en) 2014-12-31
EP2594581A3 (en) 2013-08-14
KR101511140B1 (ko) 2015-04-10
HRP20131044T1 (hr) 2013-12-06
EP2476694A3 (en) 2013-04-24
IL200478A (en) 2015-11-30
NZ602122A (en) 2014-03-28
EP2476694B1 (en) 2014-11-19
EP2121731A1 (en) 2009-11-25
IL219048A (en) 2015-07-30
RU2464275C2 (ru) 2012-10-20
KR20150064236A (ko) 2015-06-10
TWI615403B (zh) 2018-02-21
NZ591704A (en) 2012-09-28
CY1115841T1 (el) 2017-01-25
KR20140121489A (ko) 2014-10-15
KR101543623B1 (ko) 2015-08-11
IL219046A (en) 2015-02-26
CN104292299A (zh) 2015-01-21
IL219042A (en) 2016-03-31
CA2919248A1 (en) 2008-08-28
CN103351423A (zh) 2013-10-16
IL200478A0 (en) 2010-04-29
KR20090121349A (ko) 2009-11-25
AU2008218463A2 (en) 2009-11-26
CN102863514B (zh) 2014-12-10
JP2010519176A (ja) 2010-06-03
IL219047A0 (en) 2012-05-31
EP2465867A3 (en) 2012-10-10
MY155029A (en) 2015-08-28
KR101540000B1 (ko) 2015-07-29
ZA200905881B (en) 2010-05-26
KR20150018895A (ko) 2015-02-24
TWI610939B (zh) 2018-01-11
NZ602119A (en) 2014-03-28
AU2008218463A1 (en) 2008-08-28
EP2465865B1 (en) 2016-11-02
JP2013116895A (ja) 2013-06-13
PH12014501642B1 (en) 2015-12-02
HK1172042A1 (zh) 2013-04-12
HRP20150108T1 (hr) 2015-05-08
PL2465864T3 (pl) 2015-03-31
JP2014210804A (ja) 2014-11-13
TW201623325A (zh) 2016-07-01
EP2594581A2 (en) 2013-05-22
PL2121731T3 (pl) 2014-01-31
IL219041A0 (en) 2012-05-31
EP2565203A1 (en) 2013-03-06
BRPI0808421A2 (pt) 2017-08-29
CO6190536A2 (es) 2010-08-19
EP2476695A2 (en) 2012-07-18
MX2009009022A (es) 2010-03-03
KR101644871B1 (ko) 2016-08-02
EP2570428A3 (en) 2013-07-10
IL219046A0 (en) 2012-05-31
EP2465865A3 (en) 2013-07-24
EP2570429A3 (en) 2013-08-28
IL219044A (en) 2014-12-31
IL219040A0 (en) 2012-05-31
SG10201506589WA (en) 2015-09-29
EP2570430A2 (en) 2013-03-20
JP2010209060A (ja) 2010-09-24
MX337417B (es) 2016-03-03
EP2570428A2 (en) 2013-03-20
ES2435194T3 (es) 2013-12-16
SG179402A1 (en) 2012-04-27
PT2465864E (pt) 2015-01-14
CN103351423B (zh) 2016-09-28
EP2465867B1 (en) 2015-04-01
MY173379A (en) 2020-01-21
CA2678755A1 (en) 2008-08-28
CN102863514A (zh) 2013-01-09
ES2530777T3 (es) 2015-03-05

Similar Documents

Publication Publication Date Title
UA100372C2 (ru) Выделенный пептид, способный индуцировать цитотоксические т-клетки, и его применение в качестве вакцины
PL2079446T3 (pl) Preparat paliperidonu o przedłużonym uwalnianiu
UA97502C2 (ru) Кристаллическая твердая основа разагилина
GEP20105052B (en) Alcohol resistant dosage forms
EP3698631A3 (en) Methods of delivering oligonucleotides to immune cells
IN2012DN02735A (ru)
IN2012DN02702A (ru)
IN2012DN00754A (ru)
MX2009012075A (es) Inhibidores de cinasa p70 s6.
JO3635B1 (ar) مركبات صيدلانية صلبة وطرق لانتاجها
MX2010006576A (es) Composiciones y metodos para producir isopreno.
TN2012000195A1 (en) Solid dispersion of rifaximin
AU304666S (en) Bottle
MX2012009748A (es) USO DE PEPTIDOS INHIBIDORES DEL FACTOR DE CRECIMIENTO TRANSFORMANTE-BETA1(TGF-ß1) PARA EL TRATAMIENTO DE FIBROSIS Y/U OPACIDAD CORNEAL.
MX2015000338A (es) Novedosa cepa de lactobacillus crispatus.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX2012006206A (es) Preparaciones combinacion comprendiendo exosomas y corticosteroide.
IN2012DN02793A (ru)
TW200734339A (en) Forms of dolasetron mesylate and processes for their preparation
MX2009007764A (es) Formulacion de nevirapina de liberacion prolongada.
MY165088A (en) Pharmaceutical compositions comprising alisporivir
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
EP4219525A3 (en) Foxm1-derived peptide, and vaccine including same
EP4353321A3 (en) Koc1-derived peptide and vaccine including same
UA96574C2 (ru) Использование ивабрадина для получения лекарств, предназначенных для лечения эндотелиальной дисфункции